Diagnosing the decline in pharmaceutical R&D efficiency

  title={Diagnosing the decline in pharmaceutical R\&D efficiency},
  author={Jack W. Scannell and Alex Blanckley and Helen Boldon and Brian Warrington},
  journal={Nature Reviews Drug Discovery},
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (R&D). Yet the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining R&D efficiency. However, their apparent lack of impact so far… 

When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis

It is hypothesized that the average predictive validity of the stock of academically and industrially "interesting" screening and disease models has declined over time, with even small falls able to offset large gains in scientific knowledge and brute-force efficiency.

The endless frontier? The recent increase of R&D productivity in pharmaceuticals

A new set of analyses for the last decade of R&D productivity within the pharmaceutical research and development industry shows that biotechnology companies have reached levels of productivity in project development that are equivalent to those of large pharmaceutical companies.

The R&D Cost of a New Medicine

The cost of R&D for a successful new medicine has been an important policy issue at least since the 1960s. Cost estimates matter not just because of intellectual curiosity or for industry

The Endless Frontier? The Recent Upsurge of R&D Productivity in Pharmaceuticals

It is shown that the observed increased performance in clinical trials is mostly due to the contribution of biotech-nological companies, while pharmaceutical companies have significantly improved their performances in identifying false positives in preclinical research.

Changing R&D models in research-based pharmaceutical companies

Research-based pharmaceutical companies need to be aware of the key factors, which impact the rate of innovation, R&D cost and probability of success, as they challenge the model of an innovation-driven pharmaceutical industry.

Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis

An adaptive trial design with the potential to increase success rates of clinical trials by 4 percentage points could lower development costs for a new drug from 2.6 to 2.2bn USD, which would free up an additional 4.2 billion USD for investment into pharmaceutical R&D to bring about drug innovations.

Drug discovery goes back to school: changing ecosystem of drug discovery and the rising role of academia

  • B. Slusher
  • Medicine
    Journal of the peripheral nervous system : JPNS
  • 2014
As the pharmaceutical industry has been reducing its efforts in early drug discovery, there has been a simultaneous increase in the NIH’s involvement in drug discovery and translation science.

Discontinued drugs in 2012: cardiovascular drugs

The analysis of cardiovascular drugs dropped from clinical development in 2012 shows that the attrition is highest in Phase II trials and financial and strategic factors and lack of clinical efficacy are the principal reasons for these disappointments.

1 New Trends in Drug Discovery

Productivity in drug discovery has been a prominent topic over the past years. The decline of number of new drug approvals and the parallel increase in research and development (R&D) costs have been

Scientific real-time research problem-solving and pharmaceutical innovation

A perspective on these challenges is offered, and certain arguments in support of novel, technologically enabled approaches to scientific problem-solving are provided.



The productivity crisis in pharmaceutical R&D

This study examines the decline of R&D productivity in pharmaceuticals in the past two decades and shows that this decline is associated with an increasing concentration ofR&D investments in areas in which the risk of failure is high, which correspond to unmet therapeutic needs and unexploited biological mechanisms.

A New Look at the Returns and Risks to Pharmaceutical R&D

The study finds that the performance of new drugs introduced during the latter half of the 1970s was markedly better than that of early 1970s introductions, consistent with the more rapid rate of industry growth in real R&D expenditures.

Rebuilding the R&D engine in big pharma.

A cultural revolution and a broad transformation of the organization are necessary first steps to rebuilding the R&D engine, the GlaxoSmithKline CEO says.

How to improve R&D productivity: the pharmaceutical industry's grand challenge

A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.

Why has R&D productivity declined in the pharmaceutical industry?

  • R. Ruffolo
  • Business
    Expert opinion on drug discovery
  • 2006
Some of the areas where those who manage large R&D organisations may focus to improve R&S productivity are focused on, including cost-containment and maximum use of resources.


  • A. Smith
  • Political Science
    Dental student
  • 1965
Basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs are reviewed and the role of expected profits in private firms' decisions about investing in drug R&D is examined.

Identifying R&D outliers

An analysis identifying companies — which are term ‘outliers’ — that seem to have been more successful in counteracting the overall industry trend of declining R&D productivity is presented, and an initial assessment of possible characteristics differentiating them from their less successful peers is provided.

R&D strategy in the U.S. pharmaceutical industry

Lessons from 60 years of pharmaceutical innovation

  • B. Munos
  • Political Science, Biology
    Nature Reviews Drug Discovery
  • 2009
Analysis of the record of pharmaceutical innovation by analysing data on the companies that introduced the ∼1,200 new drugs that have been approved by the FDA since 1950 shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it.